ABN/ARSN

Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

na Pharmaceuticals Limited		15 088 417 403			
the entity) give ASX the following	information.				
ormation about buy-back					
Type of buy-back	On-market buy-back				
Date Appendix 3C was given to ASX	13 September 2012				
Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day					
	Before previous day	Previous day			
Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	39,030,935	375,137			
Total consideration paid or payable for the shares/units	\$27,239,176	\$276,776			
•		•			
	Type of buy-back  Date Appendix 3C was given to ASX  al of all shares/units bought been received, before, and  Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received  Total consideration paid or	the entity) give ASX the following information.  Type of buy-back  Date Appendix 3C was given to ASX  Type of all shares/units bought back, or in relation to be been received, before, and on, previous day  Before previous day  Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received  Total consideration paid or \$27,239,176			

		Before p	reviou	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.7900	price	paid:	Highest price paid: \$0.7500
		Lawat			Lowest price paid: \$0.7300
		\$0.6250	price	paid:	Highest price allowed under rule 7.33: \$0.7896

## How many shares/units may still be bought back?

6	If the company/trust has disclosed	79,224,280
	an intention to buy back a	
	maximum number of shares/units	
	- the remaining number of	
	shares/units to be bought back	
	_	

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 23 April 2013

(Director/Company secretary)

Print name: SUE MORGAN